Business
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences.
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n\n\n\n\nCAMBRIDGE, Mass., June 16 /CNW/ -- Vertex Pharmaceuticals\nIncorporated (Nasdaq: VRTX) will webcast its corporate presentations at\nNASDAQ's 17th Investor Program on Wednesday, June 21, 2006 at 2:45 p.m.\nBritish Summer Time (BST) (9:45 a.m. EDT) and at the Piper Jaffray London\nHealthcare Conference on Thursday, June 22, 2006 at 9:20 a.m. BST (4:20 a.m.\nEDT). The presentations will be delivered by John Alam, M.D., Executive Vice\nPresident, Medicines Development and Chief Medical Officer of Vertex.\nThe presentations will be webcast live and may be accessed by visiting the\nVertex website at http://www.vrtx.com. A replay of the webcasts will also be\navailable on the Company's website for two weeks following the presentations.\nTo access the webcasts, go to Vertex's website and select the 'NASDAQ 17th\nAnnual Investor Program' or the 'Piper Jaffray London Healthcare Conference'\nfrom the 'Events & Presentations' page. To ensure a timely connection, it is\nrecommended that users register at least 15 minutes prior to the scheduled\nwebcast.\n\nAbout Vertex\nVertex Pharmaceuticals Incorporated is a global biotechnology company\ncommitted to the discovery and development of breakthrough small molecule\ndrugs for serious diseases. The Company's strategy is to commercialize its\nproducts both independently and in collaboration with major pharmaceutical\ncompanies. Vertex's product pipeline is principally focused on viral\ndiseases, inflammation, autoimmune diseases and cancer. In collaboration with\nGlaxoSmithKline, Vertex co-promotes the HIV protease inhibitor, Lexiva.\n\nLexiva is a registered trademark of the GlaxoSmithKline group of\ncompanies.\n\nVertex's press releases are available at http://www.vrtx.com.\n\nVertex Contact:\nLora Pike, Manager, Investor Relations, (617) 444-6755\n\n\n\n","length":1885,"tagName":"div"}]